Results 81 to 90 of about 39,727 (183)

Supplementary Data from Alpha-1 Adrenergic Antagonists Sensitize Neuroblastoma to Therapeutic Differentiation [PDF]

open access: green, 2023
Francesca Broso   +13 more
  +5 more sources

Pharmacologic pupil dilation as a predictive test for the risk for intraoperative floppy-iris syndrome [PDF]

open access: yes, 2011
PURPOSE: To evaluate the effect of α1-adrenergic receptor antagonists (α1-ARAs) on pupil diameter and determine whether the diameter predicts intraoperative floppy-iris syndrome (IFIS).
CASUCCIO, Alessandra   +4 more
core   +1 more source

Comparison of combination therapy with tamsulosin and dutasteride or finasteride in patients with benign prostatic hyperplasia: a randomized clinical trial

open access: yesAfrican Journal of Urology
Background Based on our observations at the largest outpatient urology clinic in Iran, patients for whom finasteride is prescribed as a secondary drug to tamsulosin tend to experience earlier and more severe sexual side effects without any difference in ...
Abbas Basiri   +7 more
doaj   +1 more source

Alpha-Blocker Prescribing Trends for Ureteral Stones: A Single-Centre Study

open access: yesResearch and Reports in Urology, 2022
Liang G Qu,1,2,* Garson Chan,1– 3,* Johan Gani1,2,4 1Department of Urology, Austin Health, Heidelberg, Victoria, Australia; 2Department of Surgery, University of Melbourne, Melbourne, Victoria, Australia; 3Department of Surgery, Division of ...
Qu LG, Chan G, Gani J
doaj  

The efficacy and safety of oral Tamsulosin controlled absorption system (OCAS) for the treatment of lower urinary tract symptoms due to bladder outlet obstruction associated with benign prostatic hyperplasia: an open-label preliminary study

open access: yesInternational Brazilian Journal of Urology, 2011
AIMS: Tamsulosin, a superselective subtype alpha 1a and 1d blocker, is used for the treatment of male lower urinary tract symptoms (LUTS) commonly caused by benign prostatic hyperplasia (BPH). This prospective study evaluated the efficacy and safety of a
Bannakij Lojanapiwat   +1 more
doaj   +1 more source

Comparison of 7 α1-adrenoceptor Antagonists in Patients with Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia:A Short-term Crossover Study [PDF]

open access: yes, 2013
A crossover study was conducted to identify the best α1-adrenoceptor (α1AR) antagonist for individual patients with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). One hundred thirteen patients (mean age 70.8 years)
Araki, Motoo   +2 more
core   +1 more source

The adenylate cyclase receptor complex and aqueous humor formation. [PDF]

open access: yes, 1984
The secretory tissue of the eye, the ciliary processes, contains an enzyme receptor complex, composed of membrane proteins, the catalytic moiety of the enzyme adenylate cyclase, a guanyl nucleotide regulatory protein (or N protein), and other features ...
Caprioli, J, Sears, M
core   +1 more source

Current and prospective pharmacological targets in relation to antimigraine action [PDF]

open access: yes, 2008
Migraine is a recurrent incapacitating neurovascular disorder characterized by unilateral and throbbing headaches associated with photophobia, phonophobia, nausea, and vomiting. Current specific drugs used in the acute treatment of migraine interact with
A Bergerot   +335 more
core   +5 more sources

Stress-Dependent Impairment Of Passive-Avoidance Memory By Propranolol Or Naloxone [PDF]

open access: yes, 2011
Previous work has shown that the effect of opioid-receptor blockade on memory modulation is critically dependent upon the intensity of stress. The current study determined the effect of adrenergic-receptor blockade on memory modulation under varied ...
Atapattu, Ranga Keshani, , \u2708   +3 more
core   +2 more sources

Acute Urinary Morbidity Following Stereotactic Body Radiation Therapy for Prostate Cancer with Prophylactic Alpha-Adrenergic Antagonist and Urethral Dose Reduction [PDF]

open access: gold, 2016
Michael Repka   +12 more
openalex   +1 more source

Home - About - Disclaimer - Privacy